Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Clin |
RCV001867748 | SCV004102797 | pathogenic | X-linked severe combined immunodeficiency | 2023-11-14 | reviewed by expert panel | curation | The c.115+2T>C (NM_000206.3) variant in IL2RG occurs within the canonical donor splice site in intron 1. It is expected to disrupt RNA splicing, disrupting the reading frame, and is predicted to undergo NMD. (PVS1). This variant is absent from gnomAD v2.1.1 (PM2_Supporting). At least one patient was found in the literature showing: XY male sex (0.5pts) + T-B+NK- lymphocyte subset profile (0.5pt), total 1 point, PP4_Supporting. (PMID: 9058718; Puck JM et al). In summary, this variant meets the criteria to be classified as Pathogenic for SCID based on the ACMG/AMP criteria applied: PVS1, PP4_Supporting, and PM2_Supporting, as specified by the ClinGen SCID VCEP specifications version 1. |
Labcorp Genetics |
RCV001867748 | SCV002136328 | pathogenic | X-linked severe combined immunodeficiency | 2022-08-15 | criteria provided, single submitter | clinical testing | This variant is not present in population databases (gnomAD no frequency). For these reasons, this variant has been classified as Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. ClinVar contains an entry for this variant (Variation ID: 1368945). This variant is also known as 129(+2). Disruption of this splice site has been observed in individuals with severe combined immunodeficiency (PMID: 9058718). This sequence change affects a donor splice site in intron 1 of the IL2RG gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in IL2RG are known to be pathogenic (PMID: 9058718, 10794430). |